PlainPharmaWatch

CMS Open Payments · Program Year 2024

Endo Pharmaceuticals Inc.

Endo Pharmaceuticals Inc. reported $603,360.60 in payments to 4,960 physicians and teaching hospitals across 4,968 transactions.

See the rankings → How this is sourced
$603.4K
Total payments
4,968
Transactions
4,960
Recipients
−$1.4M
General Payments vs PY2023

Endo Pharmaceuticals Inc. reported $603,360.60 in payments to 4,960 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #724 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $121.65 per recipient across 6 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Endo Pharmaceuticals Inc. pairs above-median payment volume with an unusually diversified payment pattern across a wide recipient base.

#724
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
6
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Endo Pharmaceuticals Inc.'s CMS-reported General Payments decreased by $1.4M (−70.3%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: ENDO PHARMACEUTICALS INC.PY2023: ENDO PHARMACEUTICALS INC.PY2024: Endo Pharmaceuticals Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$2.0MPY2024$579.8K
PY2023
$1,952,230.68
PY2024
$579,807.93

How Endo Pharmaceuticals Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Endo Pharmaceuticals Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$603,361 Top 38% higher than 62% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). This entry sits in this band. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Endo Pharmaceuticals Inc.

In Program Year 2024, Endo Pharmaceuticals Inc. reported $603,360.60 in payments to 4,960 physicians and teaching hospitals across 4,968 individual transactions, an average of $121.45 per transaction and $121.65 per recipient. That total places Endo Pharmaceuticals Inc. at rank #724 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 6-category general-payment breakdown below at $198.4K (32.9% of the company's reported total, 36 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 6 types of general payments, Endo Pharmaceuticals Inc.'s largest category was "Consulting Fee" at $198.4K - 32.9% of the company's reported total.

How Endo Pharmaceuticals Inc. divides its payments

How the reported total splits across payment categories

1. Consulting Fee$198.4K2. Compensation for Services…$138.1K3. Food and Beverage$126.5K4. Grant$57.0K5. Travel and Lodging$50.4K6. Space Rental or Facility …$9.5K
Payment Type Amount Transactions
Consulting Fee $198.4K 36
Compensation for Services Other Than Consulting $138.1K 61
Food and Beverage $126.5K 4,663
Grant $57.0K 3
Travel and Lodging $50.4K 195
Space Rental or Facility Fees $9.5K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $150,930.70 (26.0%) of $579,807.93 in this company's General Payments records across 3,076 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Endo Pharmaceuticals Inc.

The five named recipients with the highest reported General Payments from this company

Damon Adamany$35.8KProsper Benhaim$35.7KCleveland Clinic Hospital$35.0KMichael Garcia$22.4KUniversity of Washington Med…$22.0K
  1. 1

    Damon Adamany

    $35,847.32 across 41 reported transactions

  2. 2

    Prosper Benhaim

    $35,673.32 across 33 reported transactions

  3. 3

    Cleveland Clinic Hospital

    $35,000.00 across 1 reported transactions

  4. 4

    Michael Garcia

    $22,424.06 across 2 reported transactions

  5. 5

    University of Washington Med Ctr

    $21,986.00 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $121.45. Average per recipient: $121.65.

Total Amount

$603,360.60

Avg per Transaction

$121.45

Avg per Recipient

$121.65

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Endo Pharmaceuticals Inc. Share

0.0%

#724 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Endo Pharmaceuticals Inc.

icotec Medical Inc.

$604.4K 1,344 recipients

Cala Health, Inc.

$602.0K 123 recipients

Arena Pharmaceuticals, Inc.

$606.7K 6 recipients

OrthoFundamentals, LLC

$607.3K 15 recipients

Bone Support Inc.

$613.3K 1,376 recipients

Aroa Biosurgery Incorporated

$591.0K 3,872 recipients

Frequently Asked Questions

How much did Endo Pharmaceuticals Inc. pay to physicians and hospitals in 2024? ▾
In Program Year 2024, CMS Open Payments recorded $603,360.60 from Endo Pharmaceuticals Inc. to physicians and hospitals across 4,968 transactions - 0.0% of all industry payments reported that year.
How many physicians received payments from Endo Pharmaceuticals Inc.? ▾
4,960 physicians and teaching hospitals received payments from Endo Pharmaceuticals Inc. in 2024, averaging $121.65 per recipient.
What types of payments did Endo Pharmaceuticals Inc. make? ▾
6 categories of general payment make up Endo Pharmaceuticals Inc.'s reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Consulting Fee" at $198.4K, representing 32.9% of the company's reported total.
How does Endo Pharmaceuticals Inc. rank among pharmaceutical companies? ▾
Endo Pharmaceuticals Inc. ranks #724 out of 1,925 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from Endo Pharmaceuticals Inc.? ▾
In 2024, Endo Pharmaceuticals Inc. averaged $121.45 per transaction across 4,968 transactions to 4,960 recipients.
Where does the payment data for Endo Pharmaceuticals Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Endo Pharmaceuticals Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.